Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A

NYSE:DNA  
5.28
+0.18 (+3.53%)
4:00:00 PM EDT: $5.28 0.00 (0.00%)
Other Pre-Announcement

Ginkgo Bioworks Provides Preliminary Unaudited 2021 Revenue Highlights And Business Review

Published: 01/12/2022 12:08 GMT
Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A (DNA) - Ginkgo Bioworks Provides Preliminary Unaudited 2021 Revenue Highlights and Business Review.
Ginkgo Bioworks - Expects to Meet Or Exceed 2021 Performance Targets for New Cell Programs, Foundry Revenue, and Biosecurity Revenue.
Ginkgo Bioworks - Preliminary Unaudited Foundry Revenue is Expected to Exceed Previously Disclosed Outlook of $100 Million for Full Year 2021.
Ginkgo Bioworks - Preliminary Unaudited Biosecurity Revenue is Expected to Exceed Previously Disclosed Outlook of $110 Million for Full Year 2021 by Over 50%.